Your browser doesn't support javascript.
loading
Adaptor Template Oligo-Mediated Sequencing (ATOM-Seq) is a new ultra-sensitive UMI-based NGS library preparation technology for use with cfDNA and cfRNA.
Dunwell, Thomas L; Dailey, Simon C; Ottestad, Anine L; Yu, Jihang; Becker, Philipp W; Scaife, Sarah; Richman, Susan D; Wood, Henry M; Slaney, Hayley; Bottomley, Daniel; Yang, Xiangsheng; Xiao, Hui; Wahl, Sissel G F; Grønberg, Bjørn H; Dai, Hongyan; Fu, Guoliang.
  • Dunwell TL; GeneFirst Ltd, Building E5, Culham Science Centre, Abingdon, OX14 3DB, UK.
  • Dailey SC; GeneFirst Ltd, Building E5, Culham Science Centre, Abingdon, OX14 3DB, UK.
  • Ottestad AL; Department of Oncology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
  • Yu J; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
  • Becker PW; GeneFirst Ltd, Building E5, Culham Science Centre, Abingdon, OX14 3DB, UK.
  • Scaife S; GeneFirst Ltd, Building E5, Culham Science Centre, Abingdon, OX14 3DB, UK.
  • Richman SD; GeneFirst Ltd, Building E5, Culham Science Centre, Abingdon, OX14 3DB, UK.
  • Wood HM; Pathology and Data Analytics, Leeds Institute of Medical Research, University of Leeds, St James University Hospital, Leeds, LS9 7TF, UK.
  • Slaney H; Pathology and Data Analytics, Leeds Institute of Medical Research, University of Leeds, St James University Hospital, Leeds, LS9 7TF, UK.
  • Bottomley D; Pathology and Data Analytics, Leeds Institute of Medical Research, University of Leeds, St James University Hospital, Leeds, LS9 7TF, UK.
  • Yang X; Pathology and Data Analytics, Leeds Institute of Medical Research, University of Leeds, St James University Hospital, Leeds, LS9 7TF, UK.
  • Xiao H; Guangzhou Biotron Technology Co., Ltd, Room 204, Zone C, Science and Technology Innovation Base, No. 80, Lanyue Road, Science City, Guangzhou, China.
  • Wahl SGF; Guangzhou Biotron Technology Co., Ltd, Room 204, Zone C, Science and Technology Innovation Base, No. 80, Lanyue Road, Science City, Guangzhou, China.
  • Grønberg BH; Department of Oncology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
  • Dai H; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
  • Fu G; Department of Oncology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
Sci Rep ; 11(1): 3138, 2021 02 04.
Article en En | MEDLINE | ID: mdl-33542447
ABSTRACT
Liquid biopsy testing utilising Next Generation Sequencing (NGS) is rapidly moving towards clinical adoption for personalised oncology. However, before NGS can fulfil its potential any novel testing approach must identify ways of reducing errors, allowing separation of true low-frequency mutations from procedural artefacts, and be designed to improve upon current technologies. Popular NGS technologies typically utilise two DNA capture approaches; PCR and ligation, which have known limitations and seem to have reached a development plateau with only small, stepwise improvements being made. To maximise the ultimate utility of liquid biopsy testing we have developed a highly versatile approach to NGS Adaptor Template Oligo Mediated Sequencing (ATOM-Seq). ATOM-Seq's strengths and versatility avoid the major limitations of both PCR- and ligation-based approaches. This technology is ligation free, simple, efficient, flexible, and streamlined, and it offers novel advantages that make it perfectly suited for use on highly challenging clinical material. Using reference and clinical materials, we demonstrate detection of known SNVs down to allele frequencies of 0.1% using as little as 20-25 ng of cfDNA, as well as the ability to detect fusions from RNA. We illustrate ATOM-Seq's suitability for clinical testing by showing high concordance rates between paired cfDNA and FFPE clinical samples.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: ARN Neoplásico / Neoplasias del Colon / Secuenciación de Nucleótidos de Alto Rendimiento / ADN Tumoral Circulante / Neoplasias Pulmonares Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: ARN Neoplásico / Neoplasias del Colon / Secuenciación de Nucleótidos de Alto Rendimiento / ADN Tumoral Circulante / Neoplasias Pulmonares Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article